232 related articles for article (PubMed ID: 2688871)
21. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
22. Flow cytometric evaluation of leukoregulin as an intrinsic molecular mediator of natural killer lymphocyte cytotoxicity.
Evans CH; Heinbaugh JA; Ransom JH
Lymphokine Res; 1987; 6(4):277-97. PubMed ID: 2448552
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin.
Basu S; Sodhi A; Singh SM; Suresh A
Immunol Lett; 1991 Mar; 27(3):199-204. PubMed ID: 2060971
[TBL] [Abstract][Full Text] [Related]
24. Taurine attenuates recombinant interleukin-2-activated, lymphocyte-mediated endothelial cell injury.
Finnegan NM; Redmond HP; Bouchier-Hayes DJ
Cancer; 1998 Jan; 82(1):186-99. PubMed ID: 9428497
[TBL] [Abstract][Full Text] [Related]
25. Lymphokine-activated killer (LAK) cells against human leukemia: augmentation of LAK-cell cytotoxicity by combinations of lymphokines or cytokines.
Teichmann JV; Ludwig WD; Seibt-Jung H; Thiel E
Haematol Blood Transfus; 1990; 33():103-9. PubMed ID: 2182408
[No Abstract] [Full Text] [Related]
26. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.
Cesano A; Visonneau S; Cioé L; Clark SC; Santoli D
Cancer Immunol Immunother; 1995 Mar; 40(3):139-51. PubMed ID: 7728772
[TBL] [Abstract][Full Text] [Related]
27. Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells.
Gunji Y; Lewis J; Gorelik E
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):663-72. PubMed ID: 2133246
[TBL] [Abstract][Full Text] [Related]
28. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
29. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
Ozdemir O; Ravindranath Y; Savaşan S
J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
[TBL] [Abstract][Full Text] [Related]
31. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
Savas B; Cole SP; Tsuruo T; Pross HF
J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
[TBL] [Abstract][Full Text] [Related]
32. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
Singh SM; Sone S; Inamura N; Ogura T
Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
[TBL] [Abstract][Full Text] [Related]
33. PGE2, but not TGF beta 2, in rabbit blastocoelic fluid regulates the cytotoxic activities of NK and LAK cells.
Bergeron D; Ouellette MJ; Lambert RD
J Reprod Immunol; 1997 Jul; 33(3):203-19. PubMed ID: 9255724
[TBL] [Abstract][Full Text] [Related]
34. The effects of recombinant human granulocyte-macrophage colony-stimulating factor on the induction of lymphokine-activated killer cells in vitro.
Okamura S; Tanaka T; Yamaga S; Omori F; Niho Y
Int J Immunopharmacol; 1991; 13(5):587-93. PubMed ID: 1783473
[TBL] [Abstract][Full Text] [Related]
35. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
36. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
de Fries RU; Golub SH
J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
[TBL] [Abstract][Full Text] [Related]
38. Differential regulation of interleukin-12- and interleukin-15-induced natural killer cell activation by interleukin-4.
Salvucci O; Mami-Chouaib F; Moreau JL; Thèze J; Chehimi J; Chouaib S
Eur J Immunol; 1996 Nov; 26(11):2736-41. PubMed ID: 8921963
[TBL] [Abstract][Full Text] [Related]
39. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.
Atzpodien J; Gulati SC; Shimazaki C; Bührer C; Oz S; Kwon JH; Kolitz JE; Clarkson BD
Oncology; 1988; 45(6):437-43. PubMed ID: 3263598
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
